Australia · Delayed Price · Currency is AUD Alcidion Group Earnings Call Transcripts
Fiscal Year 2026
-
Q3 FY2026 saw strong new sales, contract expansions, and strategic wins in the U.K. and Australia, driving recurring revenue and positive cash flow. Revenue is expected to exceed AUD 50 million for the year, with significant growth anticipated in Q4 and continued geographic expansion.
-
Record H1 revenue and EBITDA growth were driven by recurring revenue and major contract wins, especially in the UK. Guidance for FY 2026 anticipates revenue above AUD 50 million, with continued expansion into new markets and a strong sales pipeline.
-
Q2 FY 2026 saw strong contract wins, including a major Leidos expansion and selection as preferred provider for UHS Sussex, driving a 40% year-over-year increase in contracted revenue. Cash position remains robust, with positive outlook for FY 2026 pending further contract finalizations.
-
Strongest Q1 in two years with AUD 8.2M in new sales and improved cash flow. Major contract expansions and successful deployments in the UK and Australia underpin positive FY 2026 guidance, with continued focus on international growth and digital innovation.
Fiscal Year 2025
-
Record FY2025 results included strong revenue growth, improved EBITDA, and a robust cash position. Strategic focus remains on expanding the Miya Precision platform, entering new markets, and addressing healthcare sector challenges, with board renewal and shareholder engagement ongoing.
-
Record FY 2025 results included 10% revenue growth to $40.8M, ARR up 31% to $28.5M, and maiden net profit after tax of $1.7M. UK revenue surpassed ANZ, and a $39M North Cumbria contract was signed. Entering FY 2026 with $34M contracted revenue and strong growth outlook.
-
Q4 delivered record financial results, with strong new sales, cash flow, and major contract expansions. FY 2025 EBITDA is set to exceed AUD 4.5 million, and momentum continues in both core and new markets, supported by robust demand for digital health solutions.
-
Q3 delivered record new sales TCV of AUD 48.8 million, strong cash flow, and major U.K. contract wins. Upgraded FY2025 EBITDA guidance to at least AUD 3 million, with a robust pipeline and positive outlook despite NHS England restructuring.
-
First half revenue was AUD 17.6 million, down 7% year-over-year, but new contract wins drove record TCV of AUD 61.3 million and positive EBITDA. Recurring revenue reached 78% of total, and outlook remains strong with FY2025 contracted revenue at AUD 39.5 million.
-
Q2 FY25 delivered AUD 13.1 million in new sales, strong cash collections, and near break-even cash flow, with expectations for EBITDA and cash flow positivity for the full year. Major contract wins and renewals in Australia and the UK reinforce recurring revenue growth.
-
Q1 results aligned with expectations, with AUD 5.2 million in new sales and strong recurring revenue growth. Major contracts in the UK and ANZ, improved cash flow, and a positive outlook for FY 2025, targeting EBITDA break-even at AUD 36 million revenue.
Fiscal Year 2024
-
The AGM reviewed a challenging year with an 8% revenue decline but growth in recurring revenue and improved H2 profitability. Major new contracts, cost restructuring, and a focus on platform innovation underpin optimism for FY2025, with board changes and all resolutions passed.
-
FY 2024 saw revenue decline 8% to AUD 37.1 million, but annual recurring revenue grew 6%. Cost reductions led to a much smaller EBITDA loss in H2 and positive operating cash flow. Major new contracts and a strong balance sheet position the company for EBITDA-positive results in FY 2025.
-
Q4 saw strong cash flow, record cash receipts, and major contract wins, including a 10-year EPR deal with North Cumbria NHS and a 5-year partnership with Hume Rural Health Alliance. FY24 revenue is expected at AUD 37–37.5 million, with 74% recurring revenue.